China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has received Emergency Use Authorization (EUA) from Mongolia for its ReCOV, a recombinant COVID-19 vaccine co-developed by the Chinese Academy of Sciences. This authorization marks a significant milestone in the global distribution and accessibility of the vaccine.
Development and Clinical Trials of ReCOV
ReCOV is a recombinant COVID-19 vaccine developed by Recbio using innovative technologies, including a new adjuvant and protein engineering platform. The vaccine has undergone multiple late-stage clinical trials in various countries, including China, the Philippines, the UAE, Nepal, and Russia. These studies have demonstrated that ReCOV has good overall safety with mild adverse reactions, and no serious vaccine-related adverse events have been reported.
Efficacy Against Omicron Variants
In clinical studies where the Pfizer mRNA vaccine was used as a positive control, ReCOV as a booster shot induced sustained and widespread cross-neutralizing antibodies against multiple Omicron variants, such as BF.7, BA.5, BA.275, and BA.2. The neutralizing antibody levels in each subgroup were significantly superior to those of th-Fineline Info & Tech
